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Abstract
Background: One-carbon metabolism appears to play an important role in DNA methylation reaction. Evidence suggests
that a low intake of B vitamins or high alcohol consumption increases colorectal cancer risk. How one-carbon nutrients
affect the CpG island methylator phenotype (CIMP) or BRAF mutation status in colon cancer remains uncertain.
Methods: Utilizing incident colon cancers in a large prospective cohort of women (the Nurses’ Health Study), we
determined BRAF status (N=386) and CIMP status (N=375) by 8 CIMP-specific markers [CACNA1G, CDKN2A (p16), CRABP1,
IGF2, MLH1, NEUROG1, RUNX3, and SOCS1], and 8 other CpG islands (CHFR, HIC1, IGFBP3, MGMT, MINT-1, MINT-31, p14, and
WRN). We examined the relationship between intake of one-carbon nutrients and alcohol and colon cancer risk, by BRAF
mutation or CIMP status.
Results: Higher folate intake was associated with a trend towards low risk of CIMP-low/0 tumors [total folate intake
$400 mg/day vs. ,200 mg/day; the multivariate relative risk=0.73; 95% CI=0.53–1.02], whereas total folate intake had no
influence on CIMP-high tumor risks (Pheterogeneity=0.73). Neither vitamin B6, methionine or alcohol intake appeared to
differentially influence risks for CIMP-high and CIMP-low/0 tumors. Using the 16-marker CIMP panel did not substantially
alter our results. B vitamins, methionine or alcohol intake did not affect colon cancer risk differentially by BRAF status.
Conclusions: This molecular pathological epidemiology study suggests that low level intake of folate may be associated
with an increased risk of CIMP-low/0 colon tumors, but not that of CIMP-high tumors. However, the difference between
CIMP-high and CIMP-low/0 cancer risks was not statistically significant, and additional studies are necessary to confirm these
observations.
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Introduction
DNA methylation is an important epigenetic mechanism in
gene silencing and imprinting [1,2,3]. Aberrant epigenetic
silencing of tumor suppressors by CpG island hypermethylation
is commonly observed in human malignancies. The CpG island
methylator phenotype (CIMP) is characterized by propensity for
widespread CpG island hypermethylation [4,5]. High degree of
CIMP (CIMP-high) is a distinct phenotype in colorectal cancer,
associated with older age, female gender, proximal tumor location,
microsatellite instability, BRAF mutation, and high-level tumor
LINE-1 methylation [6,7,8,9]. However, etiologic factors for
CIMP-high remain largely speculative. Despite a strong associa-
tion between CIMP and BRAF mutation in colorectal cancer
[5,6,7,8], the hypothesis that BRAF mutation causes aberrant CpG
island methylation [10] has been highly controversial [11].
Recently, DNMT3B has emerged as one of causes of CpG island
methylation in tumor [12,13,14]; nonetheless, the association
between DNMT3B and CIMP in colorectal cancer is at most
modest [13] and tumor CpG island methylation appears to be
influenced by additional factors.
Folic acid and related vitamins B2,B 6 and B12, are essential for
DNA methylation and the production of purine and pyrimidine
nucleotides required for DNA synthesis. Considerable epidemio-
logical evidence suggests that a low-folate diet is associated with an
increased risk of colorectal cancer [15,16,17]. Likewise, alcohol
consumption increases colorectal cancer risk [18], likely through
its anti-folate effects [19]. We have recently shown that adequate
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LINE-1 hypomethylated colon cancer, but not against LINE-1
hypermethylated colon cancer [20]. While a recent study
demonstrated an association between folate and CpG island
methylation in normal colorectal tissue [21], how folate or other B
vitamin intake influences CpG island methylation or BRAF
mutation in tumor remains less well understood, and the literature
data are somewhat limited [22,23,24,25].
We therefore assessed whether the influence of folate on colon
cancer risk differed according to CIMP and BRAF status. For this
purpose, we used tumor specimens from a prospective cohort
study that has previously shown that folate intake was inversely
associated with the risk of colon cancer [26]. The availability of
detailed and updated information on folate intake and tumor
specimens within this cohort permitted a more comprehensive
examination of the effect of folate intake on risk of developing
CIMP-high and non-CIMP-high colon cancers as well as by BRAF
mutational status. Specificity in the association between folate and
colon cancer to particular tumor phenotypes would further
enhance the case for causality and would provide important
insights into the carcinogenic mechanisms of folate deficiency.
Materials and Methods
Study Subjects
The Nurses’ Health Study (NHS) was established in 1976 when
121,701 U.S. female registered nurses, 30 to 55 years of age,
completed a mailed questionnaire [27]. Follow-up within the
cohort currently exceeds 92%. We mailed biennial questionnaires
to update information and identify newly diagnosed cases of
cancer. In 1980, the NHS questionnaire was expanded to include
a validated assessment of diet, and updated dietary assessments
have been conducted every four years [28]. The institutional
review boards at Brigham and Women’s Hospital and the Harvard
School of Public Health approved this study and the consent
procedure.
Assessment of Nutrients
Dietary intake of various nutrients including folate, vitamin B6,
B12, and methionine were assessed by self-administered semi-
quantitative food frequency questionnaires (SFFQ), which were
completed in 1980, 1984, 1986, 1990, 1994, and 1998. Nutrient
intakes were calculated by multiplying the reported frequency of
consumption of each specified food item by the nutrient content of
the specified portion size and then summing these products for all
food items. Information on multivitamin use and the use of other
supplements was also collected, including details on which brand
name and type. An extensive database of supplement formulation
was then used to calculate specific nutrient contributions from
these supplemental sources. These nutrient contributions were
subsequently added to the specific nutrient intake from foods to
calculate a daily intake for each woman. This method of dietary
assessment has been extensively validated and its reliability
evaluated [28]. The correlation coefficient was 0.55 for the
correlation between total folate intake calculated from the 1980
questionnaire and erythrocyte folate concentrations measured in
1987 in this cohort [29]. Moreover, vitamin B6 intake as assessed
by 1980, 1984, and 1986 SFFQs has been shown to correlate with
one-week diet records, with correlations ranging from 0.54 to 0.58
[28,30].
Assessment of Other Covariates
Alcohol consumption was the sum of the values for three types
of beverages: beer, wine, and spirits. We assumed an ethanol
content of 13.1 g for a 12-ounce (38-dl) can or bottle of beer,
11.0 g for a 4-ounce (12-dl) glass of wine, and 14.0 g for a
standard portion of spirits. In validation studies, the correlation
coefficient for the correlation between alcohol consumption
derived from the 1980 SFFQ and the average of four one-week
diet records was 0.90 [31]. Other risk factors for colon cancer such
as physical exercise and body mass index have generally been
assessed biennially on the main questionnaires.
Ascertainment of Colon Cancer Cases and Tumor Tissue
Procurement
We included colon cancers reported on the biennial question-
naires between the return of the 1980 questionnaire and June 1,
2004. With permission from study participants, colon cancer was
confirmed through physicians’ review of the nurses’ medical
records. If permission was denied, we attempted to confirm the
self-reported cancer with an additional letter or phone call. We
also searched the National Death Index to identify deaths among
the nonrespondents to each two-year questionnaire. The comput-
erized National Death Index is a highly sensitive method for
identifying deaths in this cohort [32]. For all deaths attributable to
colon cancer, we requested permission from family members
(subject to state regulation) to review the medical records. We
successfully obtained specimens for 58% of cases (n=527) over 22
years of follow-up in NHS. There was no significant difference in
demographic or exposure variables between cases with available
tissue and those without available tissue [33].
Genomic DNA extraction and sequencing of BRAF
Genomic DNA from paraffin-embedded tissue was extracted,
and whole genome amplification was performed by PCR using
random 15-mer primers [34]. PCR and sequencing targeted for
BRAF codon 600 were performed as previously described [35].
Real-time PCR (MethyLight) for quantitative DNA
methylation
To determine CIMP status, we quantified DNA methylation in
eight CIMP-specific promoters. Bisulfite treatment on genomic
DNA and subsequent real-time PCR (MethyLight) [36] were
validated and performed as previously described [37]. The eight
CIMP-specific promotors that we quantified (CACNA1G, CDKN2A
(p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1)
[5,38] were selected from screening of 195 CpG islands [5,39].
CIMP-high was defined as $6/8 methylated markers using the
eight-marker CIMP panel, and CIMP-low/0 was defined as 0/8
to 5/8 methylated markers, according to the previously established
criteria [38]. In secondary analyses, we added eight more markers
(CHFR, MGMT, P14, WRN, HTC1, MINT1, MINT31, IGFBP3)
[7] for a 16-marker panel. Using this 16-marker panel, we created
two categories of CIMP (CIMP-high defined as $11/16
methylated markers; and CIMP-low/0 as 0/16 to 10/16
methylated markers). Concordance of CIMP-high diagnosis
between the 8-marker and 16-marker panels was high (0.97;
k=0.89) [7].
Statistical Analysis
We excluded women who did not complete the baseline 1980
dietary questionnaire or recorded implausible dietary data
(n=29,279), reported a baseline history of cancer (except non-
melanoma skin cancer; n=3,627), inflammatory bowel disease,
hereditary nonpolyposis colon cancer, or a familial polyposis
syndrome (n=103), or had died prior to baseline (n=1). After
these exclusions, 88,691 women were eligible for analysis and
Folate, Vitamin B6, CIMP, BRAF, Colon Cancer
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21102accrued follow-up time beginning on the month of return of their
baseline questionnaire and ending on the month of diagnosis of
colon cancer, death from other causes, or June 1, 2002, whichever
came first. In a previous analysis of this cohort, folate intake was
significantly associated with the risk of colon cancer but had no
influence on the risk of rectal cancer [26]; as a result, we did not
consider incident rectal cancer among the study participants in this
analysis. Like rectal cancer cases, cases of colon cancer for which
we were unable to quantified DNA methylation were censored
from the analyses at their date of diagnosis and were not included
as endpoints.
We calculatedincidence rates ofcolon cancerforparticipantsina
specific category of folate intake by dividing the number of incident
cases by the number of person-years. We computed relative risks
(RR) by dividing the incidence rate in one category by the incidence
rate in the reference category and used Cox proportional hazards
modeling to control for multiple variables simultaneously and to
compute 95% confidence intervals (CI). With the exception of
folate, vitamin B6, methionine, and alcohol, for which we used
baseline information in our primary analyses, we used the most
updated information for all covariates prior to each two-year
interval.
To compare the specific effect of intake of folate and other
nutrients on colon cancer risk according to CIMP and BRAF status,
we employed a previously described method of competing risk
analysis utilizing duplication method Cox regression [40,41]. This
methodology permits estimation of separate regression coefficients
fornutrient intakestratified bythetypeofoutcome[e.g.CIMP-high
cancer vs. CIMP-low/0 cancer; BRAF mutation (+) vs. (2)]. We
assessed thestatisticalsignificanceoftheinteraction between therisk
estimates according to tumor type using a likelihood ratio test that
compared the model that allowed for separate associations of folate
and other nutrients according to CIMP/BRAF status with a model
that assumed a common association. We conservatively interpreted
statistical significance of findings because of multiple hypothesis
testing. To take into account multiple testing (five one-carbon
nutrients were examined) we adjusted our significance level to
p=0.01 (=0.05/5). We used SAS version 9.1.3 (Cary, NC) for all
analyses. All P values are two-sided.
Results
Among 88,691 women included in these analyses, those with a
baseline folate intake of less than 200 mg/day were slightly more
Table 1. Baseline characteristics of the Nurses’ Health Study cohort
*.
Energy-adjusted Folate Intake, mg/day
,200 200–299 300–399 $400
Characteristic
* N=20,907 N=28,882 N=12,997 N=25,905
Dietary Intake
Y
Folate (mg/day) 159 246 341 677
Vitamin B6 (mg/day) 1.59 2.05 2.76 2.15
Vitamin B12 (mg/day) 5.55 6.45 7.78 15.06
Alcohol (g/day) 6.35 6.37 6.00 6.33
Methionine (mg/day) 1.74 1.86 1.95 1.93
Calcium (mg/day) 607 723 798 812
Beef, pork, or lamb as a main dish (servings per week) 0.44 0.37 0.32 0.33
Other Characteristics
*
Median age (yr) 46.6 46.8 46.8 46.6
Former or current smoker (%) 60 56 54 55
Pack-years
{ 23.3 20.4 18.7 19.2
Regular aspirin user (%) 31 32 32 35
Body mass index (kg/m
2)
{ 24.4 24.5 24.3 24.0
Physical activity, METS/wk (%)
1 11.1 13.8 15.8 15.6
Post-menopausal (%) 44 44 44 44
Never used hormones (%) 64 62 61 59
Past use of hormones (%) 18 19 20 22
Current use of hormones (%) 18 19 19 19
Current multivitamin use (%) 8 12 23 84
Prior lower endoscopy (%) 2 2 2 2
Colorectal cancer in a parent or sibling (%) 2 2 2 2
History of prior polyps (%) 8 8 8 8
*Dietary intake and other characteristics at baseline questionnaire in 1980 (mean value, unless otherwise indicated).
YAll values have been directly standardized according to the age distribution of the cohort.
{Pack-years were calculated for former and current smokers only.
{The body-mass index is the weight in kilograms divided by the square of the height in meters.
1METS are metabolic equivalents. This was calculated based on the frequency of physical activities (such as jogging) in 1986.
doi:10.1371/journal.pone.0021102.t001
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PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e21102Table 2. Risk of colon cancer according to baseline quintiles of one-carbon nutrient intake by CIMP expression in tumors among
88,691 women in the Nurses’ Health Study (1980–2002).
Energy-adjusted daily
one-carbon nutrient intake RR (95% CI)
* P Trend
Folate (mg) Q1 Q2 Q3 Q4
,200 200–299 300–399 $400
Cases/Person-years 100/439203 120/606372 55/273313 100/543046
All cancers
{ 1.0 0.78 (0.60–1.02) 0.75 (0.54–1.04) 0.71 (0.53–0.93) 0.06
All cancers
* 1.0 0.81 (0.62–1.06) 0.80 (0.57–1.12) 0.78 (0.59–1.05) 0.23
Cases/Person-years 80/439218 92/606395 41/273323 75/543075
CIMP-low/0
{ 1.0 0.75 (0.55–1.01) 0.70 (0.48–1.01) 0.66 (0.48–0.91) 0.04
CIMP-low/0
* 1.0 0.78 (0.58–1.05) 0.75 (0.51–1.10) 0.73 (0.53–1.02) 0.15
Cases/Person-years 20/439270 28/606450 14/273348 25/534107
CIMP-high
{ 1.0 0.91 (0.51–1.61) 0.95 (0.48–1.88) 0.88 (0.49–1.59) 0.82
CIMP-high
* 1.0 0.95 (0.53–1.68) 1.02 (0.51–2.02) 0.98 (0.54–1.77) 0.94
Methionine (g) Q1 Q2 Q3 Q4 Q5
#1.50 1.51–1.70 1.71–1.90 1.91–2.20 $2.21
Cases/Person-years 78/371363 87/371303 63/375394 62/372422 85/371052
All cancers
{ 1.0 1.1 (0.81–1.49) 0.77 (0.55–1.07) 0.75 (0.54–1.04) 0.96 (0.71–1.31) 0.81
All cancers
* 1.0 1.09 (0.80–1.49) 0.76 (0.54–1.06) 0.74 (0.53–1.04) 0.96 (0.70–1.32) 0.87
Cases/Person-years 56/371384 76/371713 51/375402 39/372445 66/371068
CIMP-low/0
{ 1.0 0.90 (0.64–1.27) 1.03 (0.70–1.51) 0.74 (0.49–1.11) 1.00 (0.69–1.43) 0.44
CIMP-low/0
* 1.0 0.75 (0.53–1.07) 0.85 (0.58–1.25) 0.65 (0.43–0.98) 1.04 (0.73–1.49) 0.48
Cases/Person-years 22/371411 11/371771 12/375349 23/372449 19/371104
CIMP-high
{ 1.0 0.39 (0.19–0.81) 0.56 (0.28–1.13) 1.06 (0.59–1.91) 0.69 (0.37–1.27) 0.37
CIMP-high
* 1.0 0.49 (0.24–1.01) 0.51 (0.25–1.04) 0.97 (0.54–1.75) 0.77 (0.41–1.42) 0.35
Vitamin B6 (mg) Q1 Q2 Q3 Q4 Q5
#1.30 1.31–1.60 1.61–2.00 2.01–3.50 $3.51
Cases/Person-years 89/375530 75/372933 70/3744309 64/371267 21/367894
All cancers
{ 1.0 0.78 (0.58–1.06) 0.66 (0.48–0.98) 0.63 (0.46–0.87) 0.74 (0.54–1.00) 0.48
All cancers
* 1.0 0.80 (0.58–1.11) 0.70 (0.48–1.01) 0.70 (0.45–1.10) 0.86 (0.56–1.33) 0.22
Cases/Person-years 72/375549 56/372946 55/374322 49/371278 56/367915
CIMP-low/0
{ 1.0 1.35 (0.98–1.96) 0.65 (0.45–0.92) 0.59 (0.41–0.86) 0.66 (0.46–0.94) 0.12
CIMP-low/0
* 1.0 1.36 (0.94–1.96) 0.68 (0.45–1.01) 0.66 (0.41–1.07) 0.77 (0.48–1.23) 0.43
Cases/Person-years 17/375591 19/372973 15/374359 15/371307 21/367944
CIMP-high
{ 1.0 1.04 (0.54–1.99) 0.74 (0.37–1.49) 0.77 (0.38–1.54) 1.05 (0.55–1.99) 0.57
CIMP-high
* 1.0 1.06 (0.55–2.06) 0.79 (0.38–1.62) 0.86 (0.40–1.85) 1.24 (0.61–2.52) 0.31
Vitamin B12 (g) Q1 Q2 Q3 Q4 Q5
#4.0 4.1–5.0 5.1–7.0 7.1–11.0 $11.1
Cases/Person-years 98/481642 60/293090 75/317891 64/391812 78/377499
All cancers
{ 1.0 0.95 (0.69–1.31) 1.08 (0.80–1.46) 0.74 (0.54–1.01) 0.89 (0.66–1.20) 0.77
All cancers
* 1.0 0.94 (0.68–1.30) 1.08 (0.80–1.47) 0.76 (0.55–1.05) 0.94 (0.69–1.28) 0.94
Cases/Person-years 75/481663 48/293100 55/317904 47/391828 63/377516
CIMP-low/0
{ 1.0 1.01 (0.70–1.45) 1.04 (0.73–1.47) 0.71 (0.49–1.02) 0.94 (0.67–1.31) 0.79
CIMP-low/0
* 1.0 1.01 (0.71–1.46) 1.04 (0.73–1.47) 0.73 (0.50–1.05) 0.99 (0.70–1.39) 0.93
Cases/Person-years 23/481706 12/293130 20/317936 17/391850 15/377553
CIMP-high
{ 1.0 0.81 (0.40–1.62) 1.23 (0.68–2.24) 0.83 (0.44–1.56) 0.73 (0.38–1.40) 0.91
CIMP-high
* 1.0 0.80 (0.40–1.62) 1.23 (0.68–2.25) 0.86 (0.46–1.62) 0.77 (0.40–1.49) 1.00
Alcohol (g) Q1 Q2 Q3 Q4
No alcohol ,5 g/day 5–14.9 g/day $15 g/day
Cases/Person-years 111/595227 139/629283 77/416138 48/221285
All cancers
{ 1.0 1.25 (0.98–1.61) 0.99 (0.74–1.33) 1.12 (0.80–1.57) 0.88
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400 mg daily folate intake or more (Table 1). They were also less
likely to use aspirin or postmenopausal hormones regularly. In
addition, only 8% of women with less than 200 mg/day folate
intake used multivitamins, whereas among those with 400 mg
folate or more daily, 84% reported current multivitamin use.
Further details have been reported elsewhere [42].
We documented 375 incident cases of colon cancer accessible
for quantifying DNA methylation during 1,861,934 person-years.
Using DNA methylation assays on these 375 colon cancers, 87
(23%) tumors were found to be CIMP-high. Similarly, BRAF
mutational status was available for 386 accessible incident colon
cancer cases documented during 1,861,927 person years, of which
86 (22%) were BRAF mutated.
As in our previous studies [18,26,43,44], we observed an inverse
association between folate and vitamin B6 intake and colon cancer
risk among all cases in our cohort (Tables 1 and 2).
We further evaluated the influence of one-carbon nutrients on
colon cancer risk according to CIMP status in colon cancer. Overall,
none of the associations examined reached statistical significance at
the conservative significance level (p=0.01). For total folate intake
(Table 2), the benefit of consumption beyond 200 mg per day
appeared to be restricted to CIMP-low/0 cancers. Compared to
women with less than 200 mg folate per day, the multivariate RR for
the development of CIMP-low/0 colon cancer among those
reporting 400 mg or more of folate intake per day was 0.73 (95%
CI, 0.53 to 1.02; P for trend=0.15) though statistical significance
was not reached. In contrast, total folate intake had no influence on
the risk of CIMP-high tumors (RR, 0.98; 95% CI, 0.54–1.77).
We further examined the influence of vitamin B6 and B12 intake
according to CIMP status (Table 2). The benefit of vitamin B6
intake also appeared confined to CIMP-low/0 cancer (multivariate
RR 0.77; 95% CI, 0.48 to 1.23 comparing extreme quintiles),
whereas B6 intake had no influence on the risk of CIMP-high
tumors. However, there was no differential effect of vitamin B12 on
colon cancer risk by tumoral CIMP status and none of the
observed associations reached statistical significance.
We also examined the influence of methionine intake and
alcohol intake according to CIMP status (Table 2). There
appeared to be a modestly greater reduction in the risk of
CIMP-high cancers with increasing methionine intake. We did not
observe a significant influence of alcohol intake on colon cancer
risk, and the effect did not appear to differ according to CIMP
status.
When using our 16-marker panel, overall, results remained
unchanged (data not shown).
Similarly, for BRAF mutation status, none of the examined
nutrients displayed a significant effect overall, or by mutational
status (Table 3).
Discussion
Our current study is a prototypical study in ‘‘Molecular
Pathological Epidemiology’’, the concept of which has been recently
described and consolidated by Ogino et al. [45]. It represents a
relatively new, specialized field of epidemiology based on the
molecular classification of cancer. In molecular pathologic
epidemiology, a known or suspected etiologic factor is examined
in relation to a specific somatic molecular change, in order to gain
insights into the carcinogenic mechanism [45]. Assume, a given
etiologic factor (lifestyle, dietary, environmental or genetic) is
hypothesized to cause a certain somatic molecular change. If we
can demonstrate a specific relationship between the etiologic factor
and the molecular change, it can provide evidence for causality. In
addition, for an individual who has a susceptibility to a specific
somatic molecular change leading to cancer, we may be able to
develop a personalized preventive measure, which targets specific
molecules or pathways [45]. Therefore, molecular pathologic
epidemiology research can contribute to deciphering the carcino-
genic process as well as optimizing preventive strategies [45].
In this prospective cohort study, we found suggestions for both
low folate and vitamin B6 intakes to be associated with an
increased risk of CIMP-low/0 colon cancers but not with that of
CIMP-high tumors. The elevation in risk was principally limited to
participants with the lowest levels of folate and vitamin B6 intake.
In addition, we observed that the effect of a higher methionine
intake on colon cancer risk modestly differed by tumoral CIMP
status, with the beneficial effect of methionine being principally
limited to CIMP-high cancer. There was no difference in the
effects of folate or B vitamins on colon cancers stratified by BRAF
status. Moreover, none of the observed associations reached
statistical significance.
Energy-adjusted daily
one-carbon nutrient intake RR (95% CI)
* P Trend
All cancers
* 1.0 1.27 (0.99–1.63) 1.01 (0.75–1.36) 1.11 (0.78–1.58) 0.98
Cases/Person-years 80/595254 113/629305 59/416154 36/221297
CIMP-low/0
{ 1.0 0.71 (0.53–0.94) 1.06 (0.76–1.48) 1.16 (0.79–1.72) 0.91
CIMP-low/0
* 1.0 0.70 (0.52–0.93) 1.08 (0.77–1.52) 1.16 (0.77–1.73) 0.79
Cases/Person-years 31/595293 26/629378 18/416189 12/221315
CIMP-high
{ 1.0 0.84 (0.50–1.41) 0.83 (0.46–1.48) 1.00 (0.51–1.95) 0.60
CIMP-high
* 1.0 0.85 (0.50–1.43) 0.84 (0.47–1.51) 1.00 (0.51–1.95) 0.67
{Age adjusted only.
*All models are adjusted for age (continuous), energy intake, gender, screening sigmoidoscopy, family history of colorectal cancer, aspirin use, smoking, physical activity
in METs, baseline body mass index, a history of colon polyps, beef intake, calcium, multi-vitamin use, and baseline folate, vitamin B6, B12, methionine, and alcohol if not
primary exposure. P for heterogeneity of the association for folate intake and CIMP-low/0 colon cancer versus folate intake and CIMP-high colon cancers=0.73
(x
2=1.31, 3 d.f.).
P for heterogeneity of the association for vitamin B6 intake and CIMP-high colon cancer and vitamin B6 intake and CIMP-low/0 colon cancers=0.63 (x
2=2.6, 4 d.f.) and
for vitamin B12 intake=0.94 (x
2=0.79, 4 d.f.). P for heterogeneity of the association for methionine intake and CIMP-high colon cancer and methionine intake and CIMP-
low/0 colon cancers=0.007 (x
2=14.097, 4 d.f.), and for alcohol intake=0.32 (x
2=3.52, 3 d.f.).
doi:10.1371/journal.pone.0021102.t002
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21102Table 3. Risk of colon cancer according to baseline quintiles of one-carbon nutrient intake by BRAF mutation status in tumors
among 88,691 women in the Nurses’ Health Study (1980–2002).
Energy-adjusted daily one-
carbon nutrient intake RR (95% CI)
* P Trend
Folate (mg) Q1 Q2 Q3 Q4 Q5
,200 200–299 300–399 $400
Cases/Person-years 102/439203 124/606368 55/273313 105/543043
All cancers
{ 1.0 0.79 (0.61–1.03) 0.73 (0.53–1.02) 0.73 (0.55–0.95) 0.10
All cancers
* 1.0 0.83 (0.63–1.08) 0.79 (0.57–1.11) 0.81 (0.61–1.08) 0.37
Cases/Person-years 79/439222 99/606387 43/273321 79/543064
BRAF mutation (2)
{ 1.0 0.70 (0.40–1.24) 0.71 (0.35–1.42) 0.80 (0.45–1.39) 0.86
BRAF mutation (2)
* 1.0 0.74 (0.42–1.30) 0.76 (0.38–1.54) 0.89 (0.51–1.57) 0.87
Cases/Person-years 23/439265 25/606455 12/273350 26/543113
BRAF mutation (+)
{ 1.0 0.81 (0.60–1.09) 0.74 (0.51–1.07) 0.71 (0.52–0.96) 0.08
BRAF mutation (+)
* 1.0 0.85 (0.63–1.15) 0.80 (0.55–1.17) 0.80 (0.57–1.09) 0.26
Methionine (g) Q1 Q2 Q3 Q4 Q5
#1.50 1.51–1.70 1.71–1.90 1.91–2.20 $2.21
Cases/Person-years 82/371361 90/371701 65/375393 63/372420 86/371052
All cancers
{ 1.0 1.08 (0.80–1.46) 0.76 (0.55–1.05) 0.72 (0.52–1.00) 0.92 (0.68–1.25) 0.62
All cancers
* 1.0 1.07 (0.79–1.45) 0.74 (0.53–1.02) 0.70 (0.50–0.98) 0.91 (0.66–1.24) 0.61
Cases/Person-years 24/371412 13/371772 12/375440 19/372454 18/371107
BRAF mutation (2)
{ 1.0 1.87 (0.95–3.68) 0.48 (0.24–0.95) 0.74 (0.41–1.36) 0.66 (0.36–1.22) 0.88
BRAF mutation (2)
* 1.0 1.90 (0.96–3.73) 0.46 (0.23–0.93) 0.73 (0.40–1.33) 0.65 (0.35–1.20) 0.87
Cases/Person-years 58/371382 77/371710 53/375400 44/372438 68/371064
BRAF mutation (+)
{ 1.0 1.31 (0.93–1.84) 0.87 (0.60–1.26) 0.71 (0.48–1.06) 1.03 (0.73–1.47) 0.64
BRAF mutation (+)
* 1.0 1.29 (0.92–1.82) 0.85 (0.58–1.24) 0.70 (0.47–1.03) 1.01 (0.71–1.45) 0.62
Vitamin B6 (mg) Q1 Q2 Q3 Q4 Q5
#1.30 1.31–1.60 1.61–2.00 2.01–3.50 $3.51
Cases/Person-years 93/375527 77/372932 70/374309 66/371265 80/367894
All cancers
{ 1.0 0.77 (0.57–1.04) 0.63 (0.46–0.87) 0.62 (0.45–0.85) 0.73 (0.54–0.99) 0.85
All cancers
* 1.0 0.77 (0.56–1.07) 0.66 (0.46–0.94) 0.66 (0.42–1.03) 0.82 (0.53–1.26) 0.52
Cases/Person-years 19/375591 15/372978 16/374359 13/371309 23/367948
BRAF mutation (2)
{ 1.0 1.37 (0.70–2.69) 0.71 (0.36–1.37) 0.60 (0.29–1.21) 1.03 (0.56–1.89) 0.28
BRAF mutation (2)
* 1.0 1.36 (0.68–2.69) 0.73 (0.37–1.47) 0.64 (0.30–1.38) 1.15 (0.58–2.28) 0.19
Cases/Person-years 74/375546 62/372940 54/374323 53/371275 57/367911
BRAF mutation (+)
{ 1.0 0.78 (0.56–1.09) 0.62 (0.43–0.87) 0.62 (0.44–0.89) 0.66 (0.46–0.93) 0.62
BRAF mutation (+)
* 1.0 0.78 (0.55–1.12) 0.64 (0.43–0.95) 0.67 (0.42–1.07) 0.73 (0.46–1.16) 0.89
Vitamin B12 (g) Q1 Q2 Q3 Q4 Q5
#4.0 4.1–5.0 5.1–7.0 7.1–11.0 $11.1
Cases/Person-years 104/481636 61/293088 75/317892 68/391811 78/377500
All cancers
{ 1.0 0.91 (0.66–1.24) 1.02 (0.76–1.37) 0.74 (0.54–1.00) 0.84 (0.62–1.12) 0.57
All cancers
* 1.0 0.90 (0.66–1.24) 1.02 (0.75–1.37) 0.76 (0.56–1.03) 0.88 (0.65–1.19) 0.72
Cases/Person-years 24/481709 11/293131 18/317938 17/391847 16/377559
BRAF mutation (2)
{ 1.0 1.41 (0.69–2.89) 1.06 (0.58–1.95) 0.80 (0.43–1.48) 0.74 (0.40–1.40) 0.95
BRAF mutation (2)
* 1.0 1.42 (0.70–2.91) 1.06 (0.57–1.95) 0.82 (0.44–1.53) 0.78 (0.42–1.48) 0.86
Cases/Person-years 80/481653 50/293098 57/317903 51/391829 62/377510
BRAF mutation (+)
{ 1.0 0.97 (0.68–1.38) 1.01 (0.72–1.42) 0.72 (0.51–1.02) 0.86 (0.62–1.21) 0.46
BRAF mutation (+)
* 1.0 0.96 (0.67–1.37) 1.00 (0.71–1.41) 0.74 (0.52–1.05) 0.92 (0.65–1.28) 0.60
Alcohol (g) Q1 Q2 Q3 Q4
No alcohol ,5 g/day 5–14.9 g/day $15 g/day
Cases/Person-years 112/595229 145/629277 81/416136 48/221285
All cancers
{ 1.0 1.29 (1.01–1.66) 1.04 (0.78–1.38) 1.11 (0.79–1.55) 0.98
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deficiency may be involved in CpG island methylation [46]. In a
Japanese population, reduced activity of the enzyme methylenete-
trahydrofolate reductase (MTHFR) due to the MTHFR codon 429
variant (rs1801131), thereby impairing folate metabolism, has
been associated with CIMP-high tumors in the proximal colon
[47]. In a Caucasian population, genetic variation in the MTHFR
rs1801131 variant appears to increase risk of CIMP-high colon
tumors [48,49] although this has not been confirmed by the
Netherlands Cohort Study data [22,50]. The relation between the
MTHFR SNP and CIMP in colon cancer is strong in combination
with low folate and methionine intake as well as high alcohol
consumption [49,51]. A more recent study suggests that low
expression of gamma-glutamyl hydrolase (GGH) is strongly
associated with CIMP-high tumors, providing further support for
a role of one-carbon metabolism in this phenotype [52].
A prior case-control study of 1,154 colon tumors assessed the
influence of one-carbon nutrient intake on CIMP as well as BRAF
status in these tumors and found them not to be associated with
either CIMP-high or BRAF mutation [51]. However, compared to
our current study, nonquantitative methylation-specific PCR on a
different CpG island panel, and a less stringent definition of
CIMP-high (2 or more of 5 markers methylated) were used in that
study. Interestingly, the authors also observed that obesity was
associated with a two-fold risk of having a non-CIMP-high tumor
[51]. In our study, after carefully adjusting for obesity, both folate
and vitamin B6 (the intake of which is highly correlated in our
population) were associated with risk of CIMP-low/0 tumors.
In another case-case study within the Netherlands Cohort
Study, colorectal cancer patients in the low folate/high alcohol
intake group are more likely to have promoter hypermethylation
than patients in the high folate/low alcohol group [53]. Notably,
the Netherlands Cohort Study has shown a possible association
between vitamin B6 and MLH1 methylation [22] and an inverse
association between MTR rs1805087 polymorphism and CIMP in
men [22].
In one of the most recent study to evaluate associations between
one-carbon metabolism and colon cancer by CIMP/BRAF status,
to date, utilizing a nested case-control approach within the
Northern Sweden Health and Disease study (190 cases and 1:2
matched controls) [24], van Guelpen et al. show a lower risk of
CIMP-low/CIMP-high colorectal tumors with very low folate
levels. Collectively, there is accumulating evidence for the
hypothesis that a balance between various metabolic intermediates
of methyl-group influences locus-specific CpG island methylation
reaction. Utilizing data from an adenoma prevention trial of folic
acid and aspirin, finally, higher RBC folate levels, but not higher
dietary folate consumption, was associated with higher methyla-
tion levels [21].
Besides influence of one-carbon nutrients, evidence suggests that
local DNA sequence context may influence assembly of a
methylation reaction machinery and locus-specific DNA methyl-
ation. Studies have shown that cis-acting elements cause allele-
specific methylation in the mammalian genome [54,55,56]. Thus,
germline variations in cis-acting elements may influence epigenetic
status including DNA methylation. The MLH1 rs1800734
promoter SNP has been associated with MLH1 promoter
methylation [57,58] and MSI [59] in colorectal cancer. Another
study has shown that MGMT rs16906252 promoter SNP is
strongly associated with MGMT promoter methylation and loss of
expression in colorectal cancer [60], and with MGMT methylation
in peripheral blood cells and normal colonic mucosa in individuals
without colorectal cancer [61,62]. It remains to be investigated
whether these or other cis-acting germline variants interact with
other one-carbon-related factors to modify susceptibility to
aberrant DNA methylation.
Our study has several important strengths. First, because we
collected detailed, updated information on a number of dietary and
lifestyle covariates relevant to colon carcinogenesis over 22 years of
follow-up and with high follow-up rates, we were able to examine
long-term exposures to one-carbon nutrients and to take into
consideration important confounding factors. Second, our study is
prospective, eliminating concerns on differential recall bias,
particularly with regard to our dietary assessments. Any remaining
bias from exposure misclassification were thus likely nondifferential
by nature, biasing our results only toward the null. Further, we have
successfully linked these nutrients—as assessed via a semiquantita-
tive food frequency questionnaire (SFFQ)—to other relevant
endpoints in prior analyses, indicating that measurement error is
not large enough to hide any real associations.
Limitations of note relate to folate fortification, which became
mandatory in 1998 [63]. We have multiple assessments of one-
carbon nutrient intakes prior to fortification. Further, our results
remained unchanged when restricted to cases that arose prior to
folate fortification (1998), which has also been demonstrated in
prior analyses [20,42,64]. Other limitations and caveats specific to
molecular pathologic epidemiology in general have been discussed
elsewhere [45].
Energy-adjusted daily one-
carbon nutrient intake RR (95% CI)
* P Trend
All cancers
* 1.0 1.32 (1.03–1.70) 1.07 (0.80–1.43) 1.11 (0.79–1.58) 0.87
Cases/Person-years 23/595301 33/629373 18/416192 12/221319
BRAF mutation (2)
{ 1.0 0.38 (0.24–0.59) 1.21 (0.61–2.08) 1.35 (0.67–2.71) 0.75
BRAF mutation (2)
* 1.0 0.68 (0.40–1.17) 1.16 (0.62–2.15) 1.36 (0.67–2.74) 0.80
Cases/Person-years 89/595247 112/629303 63/416150 36/221294
BRAF mutation (+)
{ 1.0 1.84 (1.42–2.38) 1.48 (1.09–2.00) 1.52 (1.05–2.21) 0.84
BRAF mutation (+)
* 1.0 1.29 (0.97–1.70) 1.05 (0.75–1.46) 1.05 (0.71–1.56) 0.75
{Age adjusted only.
*All models are adjusted for age (continuous), energy intake, gender, screening sigmoidoscopy, family history of colorectal cancer, aspirin use, smoking, physical activity
in METs, baseline body mass index, a history of colon polyps, beef intake, calcium, multi-vitamin use, and baseline folate, vitamin B6,B 12, methionine, and alcohol if not
primary exposure.
doi:10.1371/journal.pone.0021102.t003
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21102We cannot exclude the possibility of residual confounding as a
potential explanation for our findings; nonetheless, in our
multivariate analyses which included many known or suspected
risk factors for colon cancer, the multivariate risk estimates did not
materially differ from the age-adjusted results. Further, we were
unable to obtain tumor tissue from all cases of confirmed colon
cancer detected in the Nurses’ Health Study cohort, but the risk
factors in these cases did not appreciably differ from those in cases
with tumor tissue available. Finally, even prior to mandated
fortification in 1998 [63], our participants still had relatively high
folate and vitamin B6 levels. It is therefore possible that we might
have found even stronger associations in the present study if our
folate levels would have included an even lower range.
In summary, we demonstrate that the reduced risk of colon
cancer associated with replete folate status is somewhat limited to
CIMP-low/0 cancers. Additional studies are necessary to elucidate
the exact mechanism of an abnormality in one-carbon metabolism
leading to aberrant CpG island methylation.
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